These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2566489)

  • 1. SKF 38393: vacillatory behavior in immature rats.
    Molino LJ; Shemer A; Whitaker-Azmitia PM
    Eur J Pharmacol; 1989 Feb; 161(2-3):223-5. PubMed ID: 2566489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute reduction of dopamine levels alters responses of basal ganglia neurons to selective D-1 and D-2 dopamine receptor stimulation.
    Carlson JH; Bergstrom DA; Demo SD; Walters JR
    Eur J Pharmacol; 1988 Aug; 152(3):289-300. PubMed ID: 2906003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonergic agents restore appropriate decision-making in neonatal rats displaying dopamine D1 receptor-mediated vacillatory behavior.
    Whitaker-Azmitia PM; Molino LJ; Caruso J; Shemer AV
    Eur J Pharmacol; 1990 May; 180(2-3):305-9. PubMed ID: 2365008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity.
    Morelli M; Fenu S; Garau L; Di Chiara G
    Eur J Pharmacol; 1989 Mar; 162(2):329-35. PubMed ID: 2566500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of a delta opioid receptor agonist but not a mu opioid receptor agonist with the D1-selective dopamine receptor agonist SKF 38393 markedly potentiates different behaviors in mice.
    Toyoshi T; Ukai M; Kameyama T
    Eur J Pharmacol; 1992 Mar; 213(1):25-30. PubMed ID: 1354161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors.
    Braun AR; Chase TN
    Eur J Pharmacol; 1986 Nov; 131(2-3):301-6. PubMed ID: 3493161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
    Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of continuous exposure to selective D1 and D2 dopaminergic agonists on rotational behavior in supersensitive mice.
    Winkler JD; Weiss B
    J Pharmacol Exp Ther; 1989 May; 249(2):507-16. PubMed ID: 2566677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    Eur J Pharmacol; 1994 Aug; 260(2-3):237-41. PubMed ID: 7988649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-1/D-2 behavioural interactions in the rat involving striatal dopamine D-1 receptors.
    Starr MS
    Eur J Pharmacol; 1988 Jul; 151(3):479-82. PubMed ID: 3265106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434.
    Abrahams BS; Rutherford JD; Mallet PE; Beninger RJ
    Eur J Pharmacol; 1998 Feb; 343(2-3):111-8. PubMed ID: 9570457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D1 receptor stimulation increases striatal acetylcholine release in the rat.
    Damsma G; Tham CS; Robertson GS; Fibiger HC
    Eur J Pharmacol; 1990 Sep; 186(2-3):335-8. PubMed ID: 1981190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of specific dopaminergic agonists and antagonists in the open-field test.
    Bruhwyler J; Chleide E; Liégeois JF; Delarge J; Mercier M
    Pharmacol Biochem Behav; 1991 Jun; 39(2):367-71. PubMed ID: 1682946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioural evidence for the functionality of D-2 but not D-1 dopamine receptors at multiple brain sites in the 6-hydroxydopamine-lesioned rat.
    Fletcher GH; Starr MS
    Eur J Pharmacol; 1987 Jun; 138(3):407-11. PubMed ID: 2957221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-1 dopamine agonist administration reduces the threshold for convulsions produced by pilocarpine.
    Barone P; Palma V; Parashos SA; Marin C; Chase TN; Campanella G
    Boll Soc Ital Biol Sper; 1989 Apr; 65(4):337-41. PubMed ID: 2570598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour.
    Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
    Biochem Pharmacol; 1995 May; 49(9):1185-93. PubMed ID: 7763300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced oral activity response to A77636 in neonatal 6-hydroxydopamine-lesioned rats.
    Huang NY; Kostrzewa RM
    Eur J Pharmacol; 1994 Feb; 253(1-2):163-6. PubMed ID: 7912196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.